Compare · NVO vs PFE
NVO vs PFE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $206.96B, about 1.3x PFE ($159.99B).
- Over the past year, NVO is down 17.0% and PFE is up 11.7% - PFE leads by 28.7 points.
- PFE has been more active in the news (12 items in the past 4 weeks vs 8 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- Pfizer Inc.
- Price
- $46.73+1.19%
- $28.07+0.88%
- Market cap
- $206.96B
- $159.99B
- 1M return
- -3.03%
- +12.30%
- 1Y return
- -17.03%
- +11.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest NVO
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PFE
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
- SEC Form 13F-HR filed by Pfizer Inc.
- Chairman & CEO Bourla Albert bought $1,000,920 worth of shares (38,000 units at $26.34), increasing direct ownership by 10% to 429,173 units (SEC Form 4)
- SVP & Controller Damico Jennifer B. sold $83,261 worth of shares (3,278 units at $25.40), decreasing direct ownership by 10% to 28,611 units (SEC Form 4)
- Director Blaylock Ronald E bought $998,821 worth of shares (39,231 units at $25.46), increasing direct ownership by 142% to 66,938 units (SEC Form 4)
- Director Buckley Mortimer J bought $960,369 worth of shares (37,632 units at $25.52) (SEC Form 4)
- NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off
- SEC Form 10-Q filed by Pfizer Inc.
- Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits